Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Roche’s $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company.

Cayman Islands-based Legacy Pharma is run by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Bashing accelerated approval isn’t supported by the data

The Food and Drug Administration’s accelerated approval program aims to speed “approval of drugs that treat serious conditions, and fill an unmet medical need based

April 23, 2024

JAPAC Drug Development: Safety & Regulatory Requirements

Dr. Jayawant Fuke, Senior Director of Lifecycle Safety, IQVI Hye Jin Choi, R. Ph., Sr. Director of Regulatory Affairs and Drug Development Solutions, IQVIA Asia

April 16, 2024

Confirmed: Spinal Cord Injury Can Suppress Immune Function

Prior observations that patients suffering spinal cord injuries are prone to develop infections may now have an explanation. Biomarkers of immune activity were depressed for

July 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.